Research progress of IL-17A in radiation-induced lung injury
10.3760/cma.j.cn113030-20250311-00096
- VernacularTitle:IL-17A在放射性肺损伤中的研究进展
- Author:
Yibo ZHAO
1
;
Yang YANG
1
;
Hong GE
1
Author Information
1. 郑州大学附属肿瘤医院（河南省肿瘤医院）放疗科，郑州 450008
- Publication Type:Journal Article
- Keywords:
Lung injury, radiation-induced;
Interleukin-17A;
Inflammatory response;
Pulmonary fibrosis
- From:
Chinese Journal of Radiation Oncology
2025;34(12):1257-1263
- CountryChina
- Language:Chinese
-
Abstract:
Radiation-induced lung injury (RILI) is one of the most common complications of thoracic radiotherapy, seriously affecting patients' quality of life and survival. The mechanisms underlying RILI and its therapeutic strategies have long been major focuses of research. Interleukin-17A (IL-17A), an important pro-inflammatory cytokine, has recently attracted increasing attention in studies of RILI. IL-17A regulates immune responses through multiple signaling pathways-not only promoting the recruitment of neutrophils during the acute phase of RILI, but also accelerating pulmonary fibrosis during the chronic phase by enhancing the activity of fibrogenic factors. Thus, IL-17A is considered a promising new therapeutic target for RILI. This review summarizes the mechanisms of IL-17A in RILI, discusses the prospects and challenges of targeting IL-17A for RILI treatment, and provides a theoretical basis for optimizing clinical intervention strategies.
